NZ702803A - Cns delivery of therapeutic agents - Google Patents

Cns delivery of therapeutic agents

Info

Publication number
NZ702803A
NZ702803A NZ702803A NZ70280311A NZ702803A NZ 702803 A NZ702803 A NZ 702803A NZ 702803 A NZ702803 A NZ 702803A NZ 70280311 A NZ70280311 A NZ 70280311A NZ 702803 A NZ702803 A NZ 702803A
Authority
NZ
New Zealand
Prior art keywords
therapeutic agents
cns delivery
composition
concentration
enzyme
Prior art date
Application number
NZ702803A
Other languages
English (en)
Inventor
Zahra Shahrokh
Pericles Calias
Jing Pan
Jan Powell
Lawrence Charnas
Thomas Mccauley
Teresa Leah Wright
Richard Pfeifer
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45352777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ702803(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Priority claimed from NZ605865A external-priority patent/NZ605865A/en
Publication of NZ702803A publication Critical patent/NZ702803A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
NZ702803A 2010-06-25 2011-06-25 Cns delivery of therapeutic agents NZ702803A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09
NZ605865A NZ605865A (en) 2010-06-25 2011-06-25 Cns delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
NZ702803A true NZ702803A (en) 2017-05-26

Family

ID=45352777

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ702803A NZ702803A (en) 2010-06-25 2011-06-25 Cns delivery of therapeutic agents
NZ702800A NZ702800A (en) 2010-06-25 2011-06-25 Methods and compositions for cns delivery of heparan n-sulfatase

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ702800A NZ702800A (en) 2010-06-25 2011-06-25 Methods and compositions for cns delivery of heparan n-sulfatase

Country Status (24)

Country Link
US (17) US9814764B2 (enExample)
JP (22) JP6250616B2 (enExample)
CN (4) CN104857504A (enExample)
AR (6) AR082025A1 (enExample)
BR (1) BR112012033214B1 (enExample)
CA (1) CA3171308A1 (enExample)
CL (7) CL2012003656A1 (enExample)
DK (3) DK3626258T3 (enExample)
ES (3) ES2858726T3 (enExample)
HK (1) HK1214149A1 (enExample)
HR (3) HRP20211660T1 (enExample)
HU (6) HUE046409T2 (enExample)
LT (3) LT3626258T (enExample)
MX (1) MX354776B (enExample)
NZ (2) NZ702803A (enExample)
PE (8) PE20130578A1 (enExample)
PL (1) PL2588130T3 (enExample)
PT (6) PT3626258T (enExample)
RS (3) RS62620B1 (enExample)
RU (1) RU2761342C2 (enExample)
SI (3) SI3103469T1 (enExample)
SM (1) SMT201600385B (enExample)
TW (9) TW201701899A (enExample)
UA (3) UA129740C2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
JP5901877B2 (ja) 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
RU2012154576A (ru) 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
US20220133863A1 (en) * 2010-06-25 2022-05-05 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
CN104857504A (zh) 2010-06-25 2015-08-26 夏尔人类遗传性治疗公司 芳基硫酸酯酶a cns递送的方法和组合物
BR112012033216B1 (pt) 2010-06-25 2022-10-11 Shire Human Genetic Therapies, Inc Uso de uma formulação estável compreendendo uma proteína arilsulfatase a (asa) e formulação estável para administração intratecal
UA115648C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Доставка терапевтичних агентів до цнс
EP4338797A3 (en) 2011-12-02 2024-06-12 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US9682129B2 (en) * 2011-12-23 2017-06-20 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
CA2912678C (en) * 2013-05-15 2023-10-10 Regents Of The University Of Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA2985235A1 (en) 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
PL3397270T3 (pl) * 2015-12-30 2024-08-19 Green Cross Corporation Kompozycje do zastosowania w leczeniu zespołu huntera
EP4275751A3 (en) 2016-02-24 2023-12-27 BioMarin Pharmaceutical Inc. Improved naglu fusion protein formulation
WO2017181113A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
WO2019060662A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania GENE THERAPY FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSE TYPE II
EP3760220B1 (en) * 2018-02-28 2025-02-19 Seikagaku Corporation A package comprising lyophilized chondroitinase abc and method for manufacturing the same
CN108534695A (zh) * 2018-05-04 2018-09-14 无锡恩特卫自动化检测设备有限公司 一种基于机器视觉系统的瓶塞漏酒检测方法及装置
KR102671857B1 (ko) * 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
KR20210024082A (ko) 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제
JP7253771B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP7253770B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
CN113283465B (zh) * 2021-04-02 2022-04-29 电子科技大学 一种弥散张量成像数据分析方法及装置
CN117999278A (zh) 2021-06-21 2024-05-07 裘美娜治疗公司 再生性多肽及其用途
CN115116623A (zh) * 2022-06-28 2022-09-27 深圳市儿童医院 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端
WO2025054521A1 (en) * 2023-09-07 2025-03-13 Juvena Therapeutics, Inc. Igf2 fusion protein formulations and therapeutic uses thereof
WO2025075929A1 (en) * 2023-10-02 2025-04-10 Neurona Therapeutics Inc. Methods of treating seizure activity

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133001A (en) * 1959-11-26 1964-05-12 Muset Pedro Puig Stabilization of enzymes
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
ES2185117T3 (es) 1997-08-22 2003-04-16 Seikagaku Kogyo Co Ltd Agente terapeutico para disco intervertebral herniado.
KR20010101131A (ko) 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US7412285B2 (en) 1999-04-09 2008-08-12 Oncostim, Inc. Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy
US6368315B1 (en) 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US20020099025A1 (en) * 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US6866844B2 (en) * 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
AU2002256423B2 (en) 2001-04-30 2008-07-24 Zystor Therapeutics, Inc. Subcellular targeting of therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030040479A1 (en) 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
AU2002347910A1 (en) 2001-10-16 2003-04-28 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003068159A2 (en) 2002-02-11 2003-08-21 Wake Forest University Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
ES2367257T3 (es) * 2002-04-25 2011-10-31 Shire Human Genetic Therapies, Inc. Tratamiento de deficit de alfa-galactosidasa a.
AU2003237314B2 (en) 2002-05-29 2010-03-04 Biomarin Pharmaceutical Inc. Targeted therapeutic proteins
EP1426069A1 (en) 2002-12-02 2004-06-09 Diana Evelyn Miller Drug delivery system
EP1587923B1 (en) 2003-01-22 2011-08-24 Duke University Improved constructs for expressing lysosomal polypeptides
CN102586205A (zh) 2003-01-31 2012-07-18 纽约大学西奈山医学院 酶和酶的活性部位特异性陪伴分子的组合
JP5036302B2 (ja) 2003-02-10 2012-09-26 ティオー − ビービービー ホールディング ベスローテン フェンノートシャップ 炎症状態下に血液脳関門で示差的（ｄｉｆｆｅｒｅｎｔｉａｌｌｙ）に発現される核酸
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005002515A2 (en) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
JP4586027B2 (ja) * 2004-01-30 2010-11-24 シャイア ファーマシューティカルズ アイルランド リミテッド 組換えアリールスルファターゼａの製造及び精製
US20060029656A1 (en) 2004-02-03 2006-02-09 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
EP1720405A4 (en) 2004-02-06 2008-08-27 Biomarin Pharm Inc PREPARATION OF STRONG PHOSPHORYLATED LYSOSOMAL ENZYMES AND THEIR USE
JP4914224B2 (ja) 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
UA11577U (en) 2004-04-21 2006-01-16 Academician A P Romodanov Inst Device for intrathecal drug administration into spinal canal
CA2565972A1 (en) * 2004-06-15 2005-12-29 Baxter International Inc. Ex-vivo application of solid microparticulate therapeutic agents
EP1781805B1 (en) * 2004-08-11 2009-12-09 Basf Se Enzyme-based time temperature indicator
IL165334A0 (en) * 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
JPWO2006121199A1 (ja) * 2005-05-11 2008-12-18 日本ケミカルリサーチ株式会社 脂質小胞体組成物
WO2006133446A2 (en) 2005-06-08 2006-12-14 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
MX392030B (es) 2006-02-09 2025-03-21 Genzyme Corp Agentes y usos de los mismos para prevenir y/o tratar enfermedades neurológicas
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
EP2628746B1 (en) 2006-04-04 2019-01-09 Chiesi Farmaceutici S.p.A. A process for the concentration of a polypeptide
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
US20080076120A1 (en) 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
WO2008070769A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
WO2008109677A2 (en) 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
JP5341756B2 (ja) 2007-06-29 2013-11-13 国立大学法人名古屋大学 神経障害に基づく機能不全の改善剤およびＲｈｏキナーゼ活性化抑制剤
WO2009017005A1 (ja) 2007-07-27 2009-02-05 Sharp Kabushiki Kaisha 移動局装置、基地局装置、通信システム及びプログラム
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
WO2009062348A1 (en) * 2007-11-14 2009-05-22 Institute Of Microbiology, Chinese Academy Of Sciences Methods for inhibiting influenza virus infection and their drugs
NZ622583A (en) 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
MX2010007846A (es) 2008-01-18 2010-10-05 Biomarin Pharm Inc Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas.
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009131698A2 (en) 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
US20110223147A1 (en) 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
UA115648C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Доставка терапевтичних агентів до цнс
WO2011163651A2 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
RU2012154576A (ru) * 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
NZ702801A (en) 2010-06-25 2016-08-26 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
PL2593131T3 (pl) 2010-06-25 2020-01-31 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun
CN104857504A (zh) 2010-06-25 2015-08-26 夏尔人类遗传性治疗公司 芳基硫酸酯酶a cns递送的方法和组合物
BR112012033216B1 (pt) 2010-06-25 2022-10-11 Shire Human Genetic Therapies, Inc Uso de uma formulação estável compreendendo uma proteína arilsulfatase a (asa) e formulação estável para administração intratecal
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
US8580922B2 (en) * 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US10603364B2 (en) 2014-08-11 2020-03-31 Shire Human Genetic Therapies, Inc. Lysosomal targeting and uses thereof
BR112017002741A2 (pt) 2014-08-11 2018-02-27 Shire Human Genetic Therapies, Inc peptídeos contendo manose-6-fosfato fundidos a enzimas lisossômicas
EP3220958A1 (en) 2014-10-24 2017-09-27 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
US9673835B1 (en) 2015-12-04 2017-06-06 Taiwan Semiconductor Manufacturing Co., Ltd. Pipelined SAR with TDC converter

Also Published As

Publication number Publication date
JP2016040335A (ja) 2016-03-24
JP2021167340A (ja) 2021-10-21
TW201206465A (en) 2012-02-16
HK1214149A1 (zh) 2016-07-22
JP2017214434A (ja) 2017-12-07
LT3626257T (lt) 2021-12-10
PE20170938A1 (es) 2017-07-13
HUE046856T2 (hu) 2020-03-30
JP6346162B2 (ja) 2018-06-20
US20250375506A1 (en) 2025-12-11
TWI790444B (zh) 2023-01-21
US12161702B2 (en) 2024-12-10
TW201726161A (zh) 2017-08-01
JP2018002735A (ja) 2018-01-11
JP2018002734A (ja) 2018-01-11
US20160158324A1 (en) 2016-06-09
US20230026836A1 (en) 2023-01-26
PE20130589A1 (es) 2013-05-19
CN104857504A (zh) 2015-08-26
JP2022024176A (ja) 2022-02-08
HUE052944T2 (hu) 2021-05-28
TW201212936A (en) 2012-04-01
MX354776B (es) 2018-03-20
US20220133862A1 (en) 2022-05-05
UA129740C2 (uk) 2025-07-23
US20180071212A1 (en) 2018-03-15
CN106139133B (zh) 2020-12-04
US12121569B2 (en) 2024-10-22
RS61683B1 (sr) 2021-05-31
CL2012003656A1 (es) 2013-07-19
PE20130579A1 (es) 2013-05-19
JP2023099216A (ja) 2023-07-11
TW201825111A (zh) 2018-07-16
US20180085438A1 (en) 2018-03-29
SI3626257T1 (sl) 2021-12-31
US9220677B2 (en) 2015-12-29
TW201701899A (zh) 2017-01-16
US11065307B2 (en) 2021-07-20
TW201815411A (zh) 2018-05-01
AR081680A1 (es) 2012-10-10
BR112012033214B1 (pt) 2020-11-03
RU2018113327A (ru) 2019-03-01
RU2017125281A3 (enExample) 2020-11-09
US11260112B2 (en) 2022-03-01
PT2593131T (pt) 2019-10-30
US20250161417A1 (en) 2025-05-22
ES2896060T3 (es) 2022-02-23
JP2021181489A (ja) 2021-11-25
TWI609694B (zh) 2018-01-01
AR081681A1 (es) 2012-10-10
ES2895655T3 (es) 2022-02-22
PL2588130T3 (pl) 2017-09-29
US9814764B2 (en) 2017-11-14
TWI602573B (zh) 2017-10-21
JP2020079297A (ja) 2020-05-28
US20190183984A1 (en) 2019-06-20
JP6466538B2 (ja) 2019-02-06
HUE046409T2 (hu) 2020-02-28
TW202112391A (zh) 2021-04-01
JP2016041755A (ja) 2016-03-31
HUE055963T2 (hu) 2022-01-28
US10456454B2 (en) 2019-10-29
JP2019038853A (ja) 2019-03-14
US20250121040A1 (en) 2025-04-17
JP2024097029A (ja) 2024-07-17
CN105664142A (zh) 2016-06-15
HRP20211660T1 (hr) 2022-02-04
CL2012003655A1 (es) 2013-04-19
MX2013000321A (es) 2013-04-03
AR081679A1 (es) 2012-10-10
HRP20211520T1 (hr) 2021-12-24
PE20130648A1 (es) 2013-07-03
JP2023062114A (ja) 2023-05-02
PE20130637A1 (es) 2013-06-13
US10646554B2 (en) 2020-05-12
AR081678A1 (es) 2012-10-10
DK3103469T3 (en) 2021-02-22
CA3171308A1 (en) 2011-12-29
JP7448507B2 (ja) 2024-03-12
CL2012003654A1 (es) 2013-06-14
PT2588130T (pt) 2016-11-25
JP6938456B2 (ja) 2021-09-22
AR082025A1 (es) 2012-11-07
JP6898909B2 (ja) 2021-07-07
US20170042978A1 (en) 2017-02-16
RU2018113327A3 (enExample) 2021-07-21
JP2020079298A (ja) 2020-05-28
JP7543459B2 (ja) 2024-09-02
CN105233277B (zh) 2019-01-01
RU2761342C2 (ru) 2021-12-07
PT3103469T (pt) 2021-03-04
BR112012033214A2 (pt) 2017-05-23
PE20180130A1 (es) 2018-01-18
US12409210B2 (en) 2025-09-09
US20200113981A1 (en) 2020-04-16
NZ702800A (en) 2017-03-31
US20140271598A1 (en) 2014-09-18
US20200405825A1 (en) 2020-12-31
JP2021167341A (ja) 2021-10-21
US11471516B2 (en) 2022-10-18
US20170042977A1 (en) 2017-02-16
JP2020079244A (ja) 2020-05-28
US20230165942A1 (en) 2023-06-01
JP2023052868A (ja) 2023-04-12
HRP20210298T1 (hr) 2021-04-16
UA125060C2 (uk) 2022-01-05
JP6285409B2 (ja) 2018-02-28
TW202337489A (zh) 2023-10-01
TWI698252B (zh) 2020-07-11
PT2585104T (pt) 2019-10-30
JP6522072B2 (ja) 2019-05-29
JP7087175B2 (ja) 2022-06-20
ES2858726T3 (es) 2021-09-30
JP2019006826A (ja) 2019-01-17
HUE031036T2 (en) 2017-06-28
LT3103469T (lt) 2021-03-25
LT3626258T (lt) 2021-12-10
JP7359827B2 (ja) 2023-10-11
RU2018137304A3 (enExample) 2022-02-22
DK3626258T3 (da) 2021-09-20
PE20180801A1 (es) 2018-05-09
JP2016040337A (ja) 2016-03-24
SI3626258T1 (sl) 2021-11-30
JP2019031575A (ja) 2019-02-28
UA125743C2 (uk) 2022-06-01
HK1218719A1 (zh) 2017-03-10
PT3626257T (pt) 2021-11-12
TWI876260B (zh) 2025-03-11
CL2020000468A1 (es) 2020-09-04
TWI669128B (zh) 2019-08-21
US11065308B2 (en) 2021-07-20
DK3626257T3 (da) 2021-11-08
JP2016094451A (ja) 2016-05-26
RS62620B1 (sr) 2021-12-31
SI3103469T1 (sl) 2021-04-30
US20200046810A1 (en) 2020-02-13
CN105233277A (zh) 2016-01-13
RS62520B1 (sr) 2021-11-30
SMT201600385B (it) 2017-03-08
CL2016003159A1 (es) 2017-05-12
HUE056884T2 (hu) 2022-03-28
RU2017125281A (ru) 2019-01-31
RU2018137304A (ru) 2019-03-21
TW202506172A (zh) 2025-02-16
PT3626258T (pt) 2021-10-19
JP6250616B2 (ja) 2017-12-20
JP7591476B2 (ja) 2024-11-28
JP6797876B2 (ja) 2020-12-09
US12168041B2 (en) 2024-12-17
PE20130578A1 (es) 2013-05-19
JP6522073B2 (ja) 2019-05-29
CL2012003657A1 (es) 2013-04-19
CL2017002488A1 (es) 2017-12-15
AR081677A1 (es) 2012-10-10
JP2016037504A (ja) 2016-03-22
US20130295077A1 (en) 2013-11-07
CN106139133A (zh) 2016-11-23

Similar Documents

Publication Publication Date Title
NZ702803A (en) Cns delivery of therapeutic agents
NZ605865A (en) Cns delivery of therapeutic agents
NZ702799A (en) Methods and compositions for cns delivery of arylsulfatase a
NZ702808A (en) Methods and compositions for cns delivery of iduronate-2-sulfatase
NZ598610A (en) High concentration antibody formulations
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
NZ702801A (en) Treatment of sanfilippo syndrome type b
NZ623123A (en) A process for concentration of a polypeptide
NZ710443A (en) Method of identifying disease risk factors
NZ610556A (en) Stem cell suspension
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
MX336710B (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
JO3089B1 (ar) مشتقات ايميدازول كمثبطات لانزيمات pde10a
NZ597269A (en) Aptamer for chymase, and use thereof
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
SG179069A1 (en) Cancer stem cell-targeted and drug resistant cancer therapy
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
AR124100A2 (es) Composiciones farmacéuticas para la administración intratecal de enzimas lisosómicas
WO2009137436A3 (en) Peptide conjugates
MY183704A (en) [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE FILED DATE HAS BEEN CORRECTED TO 25/06/2011

Effective date: 20151221

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 JUN 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20180425

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2019 BY ANAQUA SERVICES

Effective date: 20180522

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2020 BY ANAQUA SERVICES

Effective date: 20190521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2021 BY ANAQUA SERVICES

Effective date: 20200520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2022 BY ANAQUA SERVICES

Effective date: 20210519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2023 BY ANAQUA SERVICES

Effective date: 20220523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2024 BY ANAQUA SERVICES

Effective date: 20230524

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20231115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250521